Set against a backdrop of fraught Sino-American relations, WuXi NextCODE hopes that a company rebrand will help ensure stability and future growth.
Reincorporated as Genuity Science, the genomic analysis and bioinformatics specialist has also restructured its operations and governance, and will be based in Boston, USA.
Shanghai-headquartered WuXi (NYSE: WX) formed the company after acquiring NextCODE Health for $65 million in 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze